Therma Bright Secures Purchase Order For Initial 100 Venowave Units From New National Distribution Partner - Valor Medical of San Antonio
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has secured an initial purchase order for 100 Venowave VW5 units from Valor Medical Solutions of San Antonio, Texas, a new national distribution partner. The order, valued at $81,955 USD ($117,952 CAD) in HCPCS code reimbursements, follows successful pilot tests of the reimbursement program.
Valor Medical and its network receive approximately 100 doctor referrals daily for vascular compression therapy solutions, with successful HCPCS code reimbursements typically processed within 30-60 days. The distributor plans to place regular orders every few weeks as they expand awareness of the Venowave VW5 solution.
This development occurs in a growing compression therapy market, valued at $4.18 billion in 2024 and projected to reach $6.72 billion by 2033, with a CAGR of 7.30%.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha ottenuto un primo ordine di acquisto per 100 unità di Venowave VW5 da Valor Medical Solutions di San Antonio, Texas, un nuovo partner nazionale per la distribuzione. L'ordine, del valore di 81.955 USD (117.952 CAD) in rimborsi codice HCPCS, arriva dopo test pilota di successo del programma di rimborso.
Valor Medical e la sua rete ricevono circa 100 riferimenti da parte di medici ogni giorno per soluzioni di terapia di compressione vascolare, con rimborsi codice HCPCS di solito elaborati entro 30-60 giorni. Il distributore prevede di effettuare ordini regolari ogni poche settimane mentre espandono la consapevolezza sulla soluzione Venowave VW5.
Questo sviluppo avviene in un mercato della terapia di compressione in crescita, valutato a 4,18 miliardi nel 2024 e previsto raggiungere 6,72 miliardi entro il 2033, con un CAGR del 7,30%.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha asegurado un pedido inicial de 100 unidades del Venowave VW5 de Valor Medical Solutions de San Antonio, Texas, un nuevo socio nacional de distribución. El pedido, valorado en 81,955 USD (117,952 CAD) en reembolsos del código HCPCS, sigue a pruebas piloto exitosas del programa de reembolso.
Valor Medical y su red reciben aproximadamente 100 referencias de médicos a diario para soluciones de terapia de compresión vascular, con reembolsos exitosos del código HCPCS que suelen procesarse en 30-60 días. El distribuidor planea realizar pedidos regulares cada pocas semanas a medida que expanden el conocimiento de la solución Venowave VW5.
Este desarrollo ocurre en un mercado de terapia de compresión en crecimiento, valorado en 4.18 mil millones en 2024 y proyectado para alcanzar 6.72 mil millones para 2033, con un CAGR del 7.30%.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 텍사스 주 샌안토니오의 새로운 국가 유통 파트너인 Valor Medical Solutions로부터 100대의 Venowave VW5 장비에 대한 초기 구매 주문을 확보했습니다. 이 주문은 HCPCS 코드 환급액으로 81,955 USD (117,952 CAD)에 해당하며, 환급 프로그램의 성공적인 파일럿 테스트에 이어 진행되었습니다.
Valor Medical과 그 네트워크는 매일 약 100건의 의사 추천을 받아 혈관 압박 치료 솔루션을 제공합니다. 일반적으로 HCPCS 코드 환급 처리는 30-60일 이내에 완료됩니다. 유통업체는 Venowave VW5 솔루션의 인지도를 확대함에 따라 몇 주마다 정기적으로 주문할 계획입니다.
이 개발은 2024년 41.8억 달러로 평가되는 성장하는 압박 치료 시장에서 이루어지며, 2033년까지 67.2억 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)은 7.30%입니다.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) a sécurisé une première commande de 100 unités du Venowave VW5 auprès de Valor Medical Solutions de San Antonio, au Texas, un nouveau partenaire national de distribution. La commande, d'une valeur de 81 955 USD (117 952 CAD) en remboursements de code HCPCS, fait suite à des tests pilotes réussis du programme de remboursement.
Valor Medical et son réseau reçoivent environ 100 recommandations de médecins par jour pour des solutions de thérapie de compression vasculaire, les remboursements de code HCPCS étant généralement traités dans les 30 à 60 jours. Le distributeur prévoit de passer des commandes régulières toutes les quelques semaines alors qu'il élargit la sensibilisation à la solution Venowave VW5.
Ce développement intervient dans un marché croissant de la thérapie par compression, évalué à 4,18 milliards de dollars en 2024 et devant atteindre 6,72 milliards de dollars d'ici 2033, avec un taux de croissance annuel composé (CAGR) de 7,30%.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) hat eine erste Bestellung über 100 Venowave VW5-Geräte von Valor Medical Solutions aus San Antonio, Texas, einem neuen nationalen Vertriebspartner, gesichert. Die Bestellung hat einen Wert von 81.955 USD (117.952 CAD) in HCPCS-Code-Rückerstattungen und folgt erfolgreichen Pilotversuchen des Rückerstattungsprogramms.
Valor Medical und sein Netzwerk erhalten täglich etwa 100 Arztüberweisungen für vaskuläre Kompressionstherapielösungen, wobei erfolgreiche HCPCS-Code-Rückerstattungen in der Regel innerhalb von 30-60 Tagen bearbeitet werden. Der Distributor plant, alle paar Wochen regelmäßige Bestellungen aufzugeben, während er das Bewusstsein für die Venowave VW5-Lösung erweitert.
Diese Entwicklung erfolgt in einem wachsenden Markt für Kompressionstherapie, der im Jahr 2024 auf 4,18 Milliarden Dollar geschätzt wird und bis 2033 voraussichtlich 6,72 Milliarden Dollar erreichen wird, mit einer jährlichen Wachstumsrate (CAGR) von 7,30%.
- Secured initial purchase order worth $81,955 USD ($117,952 CAD)
- Distribution partner receives 100 daily doctor referrals
- Regular repeat orders expected every few weeks
- Successful HCPCS code reimbursement within 30-60 days
- Operating in a market with 7.30% CAGR (2025-2033)
- None.
National Distributor And Its Network Receive Upwards Of 100 Doctor Referrals Per Day For Vascular Compression Therapy Solutions
Toronto, Ontario--(Newsfile Corp. - January 13, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that the Company has secured an initial purchase order for 100 Venowave VW5 units from a new national distribution partner Valor Medical Solutions of San Antonio, Texas. The initial purchase order is based on the success of the distributor's pilot tests around the HCPCS code reimbursement program. Valor Medical is just one of the Company's national distributors who have experienced successful pilot trials.
As a new national distribution partner of Therma Bright, Valor Medical looks to fill immediate needs of its current network of medical practitioners and their patients. The distributor, and its partners, receives upwards of 100 doctor referrals per day for vascular compression therapy solutions, and has seen great success in securing HCPCS code reimbursements within a normal 30- to 60-day timeframe. Valor Medical and its partners look to place orders on a regular basis of every few weeks, as they build greater awareness of the Venowave VW5 solution with their end clients. This initial purchase order for 100 Venowave VW5 units offers HCPCS code reimbursements that total a minimum of
"We are excited to partner with Therma Bright in offering the Venowave VW5 to our national distribution network," shared Cindy Sebek Quick, Partner of Valor Medical Solutions. "This initial 100 unit purchase will fill the immediate demand on our partners, who anticipate early adoption of this special vascular compression therapy solution. We anticipate increasing our purchase order amounts every few weeks, as we build more product awareness of this device and the HCPCS code reimbursement program. Our own business sales team, and those of our partners, receive upwards of 100 doctor referrals per business day for vascular compression therapy solutions, and this solution fits many of their immediate needs."
"It's been an exciting journey for Therma Bright and its Venowave VW5 solution," shared Rob Fia, CEO of Therma Bright. "Furthermore, it has been a pleasure working with Cindy, who has been very successful in growing her business. Our team looks forward to being part of her further growth, along with our other national distributors; helping them market, sell and distribute our device within their medical communities. We anticipate great success of Venowave VW5 sales during 2025, and will provide the market updates on our progress as required."
The global compression therapy market was valued at
About Venowave VW5
The Venowave VW5 is a compact, battery-operated peristaltic pump designed to diminish post-op pain & swelling and enhance blood circulation while harnessing the multitude of advantages that come with increased venous blood flow by
About Valor Medical Solution
Valor Medical Solutions is a fast-growing distributorship of a variety of orthopedic implants and ancillary products primarily for the orthopedic industry. The Company's focus is a patient-centric business mindset making sure that all decisions are not only made with the customer's needs in mind, but what is best for the patients that Valor serves. Valor Medical's strong relationships within the communities it serves are due to its combination of the high level of integrity, expert product knowledge, and its ability to find solutions for the customers and their communities. Learn more at https://www.valormedicalsolutions.com.
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236917
FAQ
What is the value of Therma Bright's (TBRIF) initial Venowave order from Valor Medical?
How many doctor referrals does Valor Medical receive daily for TBRIF's vascular compression therapy?
What is the expected timeframe for HCPCS code reimbursements for TBRIF's Venowave devices?
What is the projected market size for compression therapy by 2033 where TBRIF operates?
How frequently will Valor Medical place orders for TBRIF's Venowave units?
